Voyager Therapeutics (VYGR) Operating Leases (2019 - 2025)
Historic Operating Leases for Voyager Therapeutics (VYGR) over the last 7 years, with Q3 2025 value amounting to $30.5 million.
- Voyager Therapeutics' Operating Leases fell 2045.45% to $30.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.5 million, marking a year-over-year decrease of 2045.45%. This contributed to the annual value of $36.5 million for FY2024, which is 11351.94% up from last year.
- Per Voyager Therapeutics' latest filing, its Operating Leases stood at $30.5 million for Q3 2025, which was down 2045.45% from $32.6 million recorded in Q2 2025.
- In the past 5 years, Voyager Therapeutics' Operating Leases registered a high of $42.1 million during Q1 2021, and its lowest value of $17.1 million during Q4 2023.
- In the last 5 years, Voyager Therapeutics' Operating Leases had a median value of $34.6 million in 2025 and averaged $31.0 million.
- Per our database at Business Quant, Voyager Therapeutics' Operating Leases plummeted by 4745.45% in 2022 and then soared by 11512.73% in 2024.
- Quarter analysis of 5 years shows Voyager Therapeutics' Operating Leases stood at $38.6 million in 2021, then plummeted by 47.44% to $20.3 million in 2022, then decreased by 15.77% to $17.1 million in 2023, then skyrocketed by 113.52% to $36.5 million in 2024, then fell by 16.38% to $30.5 million in 2025.
- Its Operating Leases was $30.5 million in Q3 2025, compared to $32.6 million in Q2 2025 and $34.6 million in Q1 2025.